Novel multi-targeted nanoparticles for targeted co-delivery of nucleic acid and chemotherapeutic agents to breast cancer tissues

Amani, Amin; Alizadeh, Mohammad; Yaghoubi, Hashem; Nohtani, Mahdi

doi:10.1016/j.msec.2020.111494

Cited by 19 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last few years, many research groups in this field have combined some targeting elements on one nanocarrier, leading to the so-called double targeting approach. 383 Different approaches of MSNs with double targeting abilities have been developed using small molecules, such as folic acid with dexamethasone, 384 with triphenylphosphonium 385 or glucose, 386 and peptides, such as arginine–glycine–aspartate peptides with the cell penetrating peptide TAT, 387 with interleukin 13 388 or with folic acid itself, 389 to ensure the specificity and selectivity towards cancer cells.…”

Section: Potential Biomedical Treatments Using Msnsmentioning

confidence: 99%

Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Potential Biomedical Treatments Using Msnsmentioning

confidence: 99%

Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The low cost, good biodegradability, biocompatibility, encapsulation efficiency, increased stability, increased transfection efficacy, and reduced tumor growth both in vitro and in vivo make these CH NCs a better way to treat cancer. , To deliver siRNA to patients with lung cancer, cervical cancer, pancreatic cancer, and hepatocellular carcinoma using CH as the primary nanoparticle Tables and summarize recently used CH NCs, bioavailable siRNA, and anticancer drugs related to cancer type and cell line for tumor targeting in the years 2020 and 2021. ,− …”

Section: Different Types Of Ncs Used To Deliver Therapeutic Sirna And...mentioning

confidence: 99%

Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

RNA interference (RNAi) has increased the possibility of restoring RNA drug targets for cancer treatment. Small interfering RNA (siRNA) is a promising therapeutic RNAi tool that targets the defective gene by inhibiting its mRNA expression and stopping its translation. However, siRNAs have flaws like poor intracellular trafficking, RNase degradation, rapid kidney filtration, off-targeting, and toxicity, which limit their therapeutic efficiency. Nanocarriers (NCs) have been designed to overcome such flaws and increase antitumor activity. Combining siRNA and anticancer drugs can give synergistic effects in cancer cells, making them a significant gene-modification tool in cancer therapy. Our discussion of NCs-mediated siRNA delivery in this review includes their mechanism, limitations, and advantages in comparison with naked siRNA delivery. We will also discuss organic NCs (polymers and lipids) and inorganic NCs (quantum dots, carbon nanotubes, and gold) that have been reported for extensive delivery of therapeutic siRNA to tumor sites. Finally, we will conclude by discussing the studies based on organic and inorganic NCs-mediated siRNA drug delivery systems conducted in the years 2020 and 2021.

show abstract

“…A proof‐of‐concept of this approach is provided by various studies. Nanoparticles decorated with both folic acid and glucose, for instance, increased drug and silencing RNA (siRNA) transfer efficiency [ 207 ] and those decorated with both folic acid and lactobionic acid targeting the overexpressed folate and asialoglycoprotein receptors on the surface of hepatocellular carcinoma cells showed potential as well. [ 208 ] In another study, Janus mesoporous silica particles were asymmetrically decorated with folic acid for tumor targeting and triphenylphosphine able to bind to mitochondria membrane.…”

Section: Interactive Surface Propertiesmentioning

confidence: 99%

“…Glucose and structurally similar monosaccharides such as galactose can therefore be used for active tumor targeting of NCs. [ 207,253 ] Galactose binds also to asialoglycoprotein a receptor that is exclusively expressed on the surface of hepatocytes and hepatoma cells with high density. The decoration of NCs with galactose residues can enhance their accumulation in hepatocytes.…”

Section: Interactive Surface Propertiesmentioning

confidence: 99%

Bioinert, Stealth or Interactive: How Surface Chemistry of Nanocarriers Determines Their Fate In Vivo

Friedl

Nele

Rosa

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

Nanocarriers (NCs) have emerged as powerful tools to improve drug solubility, to promote drug transport across membranes, to protect their payload from premature degradation, and to deliver drugs in a controlled and targeted manner. Their performance strongly depends on the surface chemistry, which governs their interaction with the biological environment. Bioinert and stealth surface features are advantageous to avoid unintended interactions with endogenous surfaces at off‐target sites and with the immune system, whereas at the target site these carriers should be highly interactive guaranteeing intracellular delivery of their payload. These key surface properties—bioinert and stealth versus interactive at the target site—are in contradiction to each other so that the best compromise between them has to be found. Alternatively, surface structures interacting preferentially with the membrane of target cells can be utilized. Stimuli‐responsive surfaces able to convert from bioinert and stealth to interactive at the target site have been recently introduced. A deepened understanding of how these different approaches influence the performance of NCs in the body is of particular importance in order to improve their efficacy. This review focuses on the surface chemistry of NCs providing the best compromise between bioinert and stealth versus interactive features.

show abstract

Novel multi-targeted nanoparticles for targeted co-delivery of nucleic acid and chemotherapeutic agents to breast cancer tissues

Cited by 19 publications

References 53 publications

Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?

Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?

Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy

Bioinert, Stealth or Interactive: How Surface Chemistry of Nanocarriers Determines Their Fate In Vivo

Contact Info

Product

Resources

About